Case Type: Mergers & Acquisitions

Hawaiian Holdings, Inc. (Nasdaq: HA), relating to its proposed sale to Alaska Air Group, Inc. Under the terms of the agreement, HA shareholders will receive $18.00 in cash per share they own.

Graphite Bio, Inc. (Nasdaq: GRPH), relating to its proposed merger with LENZ Therapeutics. Under the terms of the agreement, GRPH shareholders will own approximately 35% of the combined company.

WaveDancer, Inc. (Nasdaq: WAVD), relating to its proposed merger with Firefly Neuroscience, Inc. Under the terms of the agreement, WAVD shareholders will own approximately 8% of the combined company.

Rover Group, Inc. (Nasdaq: ROVR), relating to its sale to affiliates of Blackstone Inc. Under the terms of the agreement, ROVR shareholders will receive $11.00 in cash pers share they own.

ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN), relating to its proposed sale to Sycona Ltd. Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.

P&F Industries, Inc. (Nasdaq: PFIN), relating to its proposed sale to ShoreView Industries. Under the terms of the agreement, PFIN shareholders are expected to receive $13.00 in cash per share they own.

Homology Medicines, Inc. (Nasdaq: FIXX), relating to its proposed merger with Q32 Bio, Inc. Under the terms of the agreement, FIXX shareholders are expected to own approximately 25% of the combined company.

GAN Limited (Nasdaq: GAN), relating to its proposed sale to Sega Sammy Creation Inc. Under the terms of the agreement, GAN shareholders will receive $1.97 in cash per share they own.

Northern Genesis Acquisition Corp. II (NYSE: NGAB), relating to its 2021 merger with Embark Technology, Inc.